Advertisement

Bullous Pemphigoid on the Areola of Breast

  • Álvaro Vargas Nevado
  • Enrique Herrera Ceballos
Chapter

Abstract

Bullous pemphigoid is the most common autoimmune bullous disease. It usually appears as a very itchy rash of urticarial or eczematous appearance, with subsequent appearance of vesicles and tense blisters on previously inflamed skin. The basis of its pathogenesis consists of the production of autoantibodies that attacks several components of the hemidesmosomes which are located in the basal membrane of the dermoepidermal junction. Localized bullous pemphigoid is a rare clinical variant of bullous pemphigoid. It normally appears in the lower extremities and it’s rarer on palms or on the breast. Several causes have been described, such as physical trauma, ultraviolet radiation, and, in the case of localized bullous pemphigoid on the breast, radiotherapy or ductal carcinoma, although it is not always possible to find an underlying cause.

References

  1. 1.
    Mutasim DF. Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management. Drugs Aging. 2010;1:1–19.CrossRefGoogle Scholar
  2. 2.
    Isohashi F, Konishi K, Umegaki N, Tanei T, Koizumi M, Yoshioka Y. A case of bullous pemphigoid exacerbated by irradiation after breast conservative radiotherapy. Jpn J Clin Oncol. 2011;41(6):811–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Mul VE, van Geest AJ, Pijls-Johannesma MC, Theys J, Verschueren TA, Jager JJ, et al. Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol. 2007;82:5–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Mul VE, Verschueren TA, van Geest AJ, Baumert BG. Bullous Pemphigoid (BP) induced by radiotherapy. Radiother Oncol. 2007;82:105.CrossRefPubMedGoogle Scholar
  5. 5.
    Anzai S, Ueo D, Fujiwara S. A case of bullous pemphigoid exacerbated by radiotherapy. Vis Dermatol. 2009;8:32–3.Google Scholar
  6. 6.
    Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol. 2002;16:241–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Luliano L, Micheletta F, Natoli S. Bullous pemphigoid: an unusual and insidious presentation of breast cancer. Clin Oncol. 2003;15(8):505.Google Scholar
  8. 8.
    Vaughan Jones SA, Salas J, McGrath JA, Palmer I, Bhogal GS, Black MM. A retrospective analysis of tissue-fixed immunoreactants from skin biopsies maintained in Michel’s medium. Dermatology. 1994;189(Suppl 1):131–2.CrossRefPubMedGoogle Scholar
  9. 9.
    Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA. 2000;284:350–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Iwata Y, Komura K, Kodera M, Usuda T, Yokoyama Y, Hara T, Muroi E, Ogawa F, Takenaka M, Sato S. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol. 2008;144:41–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol. 1989;20:458–61.CrossRefPubMedGoogle Scholar
  12. 12.
    Ingen-Housz-Oro S, Valeyrie-Allanore L, Ortonne N, Roujeau JC, Wolkenstein P, Chosidow O. Management of bullous pemphigoid with topical steroids in the clinical practice of a single center: outcome at 6 and 12 months. Dermatology. 2011;222:176–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol. 1984;111:925–8.PubMedGoogle Scholar
  14. 14.
    Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol. 1989;120:83–92.CrossRefPubMedGoogle Scholar
  15. 15.
    Fivenson D, Breneman D, Rosen G, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130:753–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Kirtschig G, Khumalo NP. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol. 2004;5:319–26.CrossRefPubMedGoogle Scholar
  17. 17.
    Heilborn JD, Ståhle-Bäckdahl M, Albertioni F, Vassilaki I, Peterson C, Stephansson E. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1999;40:741–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J. 1978;28:1190–1.CrossRefGoogle Scholar
  19. 19.
    Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krähn G, Kerscher M, Peter RU. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6 Pt 1):957–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Lourari S, Herve C, Doffoel-Hantz V, Meyer N, Bulai-Livideanu C, Viraben R, Maza A, Adoue D, Bedane C, Paul C. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol. 2011;25:1238–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Álvaro Vargas Nevado
    • 1
  • Enrique Herrera Ceballos
    • 1
  1. 1.Department of DermatologyHospital Virgen de la Victoria, Campus Universitario TeatinosMálagaSpain

Personalised recommendations